title: Radiological assessment following thermoradiation therapy for primary pleural synovial sarcoma: case report.
abstract: Primary pleural synovial sarcoma is a rare disease with poor outcomes. Although hyperthermia therapy as part of a combined treatment regimen can offer improved local tumor control, only two reports of hyperthermia therapy for synovial sarcoma have appeared in the literature, and these sarcomas were not of pleuropulmonary origin. This report of an advanced inoperable primary pleural synovial sarcoma is the first to address the use of hyperthermia therapy in combination with chemoradiotherapy for this disease, together with radiological assessment following that therapy. Computed tomography performed after thermoradiation showed a decrease in tumor size and a characteristic unenhanced low-density area in the tumor suggesting that tumor necrosis resulted from the therapy. These image findings were helpful in assessing the tumor response to thermoradiation. We believe that hyperthermia therapy combined with chemoradiotherapy should be regarded as an option for advanced primary pleural synovial sarcoma. This would give computed tomography important role in evaluating this approach.
authors.affiliation: Department of Radiology, Nihon University School of Medicine, 30-1 Oyaguchi kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan. akatsumi@med.nihon-u.ac.jp
authors.forename: Katsumi
authors.initials: K
authors.lastname: Abe
authors.forename: Toshiya
authors.initials: T
authors.lastname: Maebayashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Shizukuishi
authors.forename: Masakuni
authors.initials: M
authors.lastname: Sakaguchi
authors.forename: Satoru
authors.initials: S
authors.lastname: Furuhashi
authors.forename: Motoichiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Akihito
authors.initials: A
authors.lastname: Uematsu
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sugitani
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D006979:Hyperthermia, Induced; D007069:Ifosfamide / Q000008:administration & dosage; D009363:Neoplasm Proteins / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D013584:Sarcoma, Synovial / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics / Q000628:therapy; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C116512:SYT-SSX fusion protein; D003841:Deoxycytidine; D014750:Vincristine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide; D000093542:Gemcitabine